Marshall Wace, LLP Adaptimmune Therapeutics PLC Transaction History

Marshall Wace, LLP

  • $77.3 Billion
  • Q3 2024

A detailed history of Marshall Wace, LLP transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Marshall Wace, LLP holds 522,608 shares of ADAP stock, worth $344,921. This represents 0.0% of its overall portfolio holdings.

Number of Shares
522,608
Previous 144,880 260.72%
Holding current value
$344,921
Previous $141,000 251.77%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$0.92 - $1.39 $347,509 - $525,041
377,728 Added 260.72%
522,608 $496,000
Q2 2024

Aug 14, 2024
SELL
$0.83 - $1.47 $90,580 - $160,425
-109,133 Reduced 42.96%
144,880 $141,000
Q1 2024

May 15, 2024
BUY
$0.7 - $1.75 $177,809 - $444,522
254,013 New
254,013 $401,000
Q2 2023

Aug 14, 2023
BUY
$0.9 - $1.51 $245,412 - $411,748
272,681 New
272,681 $250,000
Q4 2022

Feb 14, 2023
BUY
$1.05 - $2.53 $93,629 - $225,602
89,171 New
89,171 $130,000
Q1 2022

May 16, 2022
SELL
$1.73 - $4.06 $982,287 - $2.31 Million
-567,796 Closed
0 $0
Q4 2021

Feb 14, 2022
SELL
$3.5 - $5.68 $3.45 Million - $5.6 Million
-986,004 Reduced 63.46%
567,796 $2.13 Million
Q3 2021

Nov 15, 2021
BUY
$3.44 - $6.37 $5.35 Million - $9.9 Million
1,553,800 New
1,553,800 $8.03 Million
Q3 2020

Nov 16, 2020
SELL
$7.66 - $10.78 $2.88 Million - $4.06 Million
-376,340 Closed
0 $0
Q2 2020

Aug 13, 2020
BUY
$2.58 - $12.1 $970,957 - $4.55 Million
376,340 New
376,340 $3.77 Million
Q1 2020

May 15, 2020
SELL
$1.2 - $4.52 $34,922 - $131,541
-29,102 Closed
0 $0
Q4 2019

Feb 14, 2020
SELL
$0.72 - $1.43 $36,105 - $71,708
-50,146 Reduced 63.28%
29,102 $35,000
Q3 2019

Nov 14, 2019
BUY
$1.43 - $3.81 $113,324 - $301,934
79,248 New
79,248 $120,000
Q1 2019

May 14, 2019
SELL
$3.63 - $6.06 $472,081 - $788,103
-130,050 Closed
0 $0
Q4 2018

Feb 14, 2019
BUY
$3.76 - $14.16 $488,988 - $1.84 Million
130,050 New
130,050 $748,000

Others Institutions Holding ADAP

# of Institutions
82
Shares Held
150M
Call Options Held
60.8K
Put Options Held
5.8K
View Full List

About Adaptimmune Therapeutics PLC

ADAP Quotes by TradingView
  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $108M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email